Literature DB >> 25178879

Host-iron assimilation: pathogenesis and novel therapies of mucormycosis.

Ashraf S Ibrahim1.   

Abstract

Mucormycosis is a fungal infection caused by organisms belonging to the order Mucorales. Although considered uncommon, mucormycosis has been steadily increasing in incidents for the last two decades. Mortality of the disease is unacceptably high despite antifungal therapy and surgical interventions. The lack of understanding of the pathogenesis of the disease and the absence of rapid diagnostic assay contribute to the poor prognosis of mucormycosis. The hyper susceptibility of patients with elevated available serum iron points to the critical role of the ability of Mucorales to acquire host iron as a critical virulence factor. Specifically patients with deferoxamine-therapy, hyperglycaemic with or without ketoacidosis, or other forms of acidosis are uniquely predisposed to mucormycosis. In this review, we discuss the molecular mechanisms of infection in these patient categories in an attempt to identify novel therapies for a disease with poor prognosis. Emphasis on the effect of glucose and free iron on host-pathogen interactions are also covered.
© 2014 Blackwell Verlag GmbH.

Entities:  

Keywords:  CotH; DKA; GRP78; deferoxamine; iron uptake; mucormycosis

Mesh:

Substances:

Year:  2014        PMID: 25178879      PMCID: PMC4461208          DOI: 10.1111/myc.12232

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  45 in total

1.  Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.

Authors:  Kieren A Marr; Rachel A Carter; Fulvio Crippa; Anna Wald; Lawrence Corey
Journal:  Clin Infect Dis       Date:  2002-02-26       Impact factor: 9.079

2.  Zygomycosis in the 1990s in a tertiary-care cancer center.

Authors:  D P Kontoyiannis; V C Wessel; G P Bodey; K V Rolston
Journal:  Clin Infect Dis       Date:  2000-06-13       Impact factor: 9.079

3.  Mucormycosis infection in dialysis patients.

Authors:  J R Boelaert; P L Vergauwe; J M Vandepitte
Journal:  Ann Intern Med       Date:  1987-11       Impact factor: 25.391

Review 4.  Zygomycetes in human disease.

Authors:  J A Ribes; C L Vanover-Sams; D J Baker
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

5.  Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies.

Authors:  J R Boelaert; M de Locht; J Van Cutsem; V Kerrels; B Cantinieaux; A Verdonck; H W Van Landuyt; Y J Schneider
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

6.  Apophysomyces elegans: an emerging zygomycete in India.

Authors:  A Chakrabarti; A Ghosh; G S Prasad; J K David; S Gupta; A Das; V Sakhuja; N K Panda; S K Singh; S Das; T Chakrabarti
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

7.  Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect.

Authors:  J R Boelaert; J Van Cutsem; M de Locht; Y J Schneider; R R Crichton
Journal:  Kidney Int       Date:  1994-03       Impact factor: 10.612

8.  Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi.

Authors:  Shahid Husain; Barbara D Alexander; Patricia Munoz; Robin K Avery; Sally Houston; Timothy Pruett; Richard Jacobs; Edward A Dominguez; Jan G Tollemar; Katherine Baumgarten; Chen M Yu; Marilyn M Wagener; Peter Linden; Shimon Kusne; Nina Singh
Journal:  Clin Infect Dis       Date:  2003-07-09       Impact factor: 9.079

9.  A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability.

Authors:  W M Artis; J A Fountain; H K Delcher; H E Jones
Journal:  Diabetes       Date:  1982-12       Impact factor: 9.461

Review 10.  The role of desferrioxamine in dialysis-associated mucormycosis: report of three cases and review of the literature.

Authors:  J R Boelaert; G F van Roost; P L Vergauwe; J J Verbanck; C de Vroey; M F Segaert
Journal:  Clin Nephrol       Date:  1988-05       Impact factor: 0.975

View more
  7 in total

Review 1.  Therapeutic Challenges of Non-Aspergillus Invasive Mold Infections in Immunosuppressed Patients.

Authors:  Frederic Lamoth; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

2.  Mucormycosis in a 40-year-old woman with diabetic ketoacidosis.

Authors:  Lauren Thomas; Sze Yen Tay; Diane Howard; Henrik Falhammar
Journal:  CMAJ       Date:  2020-04-20       Impact factor: 8.262

Review 3.  Current Treatment Options for COVID-19 Associated Mucormycosis: Present Status and Future Perspectives.

Authors:  Yasasve Madhavan; Kadambari Vijay Sai; Dilip Kumar Shanmugam; Aashabharathi Manimaran; Karthigadevi Guruviah; Yugal Kishore Mohanta; Divyambika Catakapatri Venugopal; Tapan Kumar Mohanta; Nanaocha Sharma; Saravanan Muthupandian
Journal:  J Clin Med       Date:  2022-06-23       Impact factor: 4.964

4.  Deferiprone as adjunctive treatment for patients with invasive mucormycosis: A retrospective case series.

Authors:  Maria N Chitasombat; Pimjai Niparuck
Journal:  Infect Dis Rep       Date:  2018-09-25

Review 5.  COVID-19 associated mucormycosis - An emerging threat.

Authors:  Chien-Ming Chao; Chih-Cheng Lai; Wen-Liang Yu
Journal:  J Microbiol Immunol Infect       Date:  2022-01-13       Impact factor: 10.273

6.  Serum iron indices in COVID-19-associated mucormycosis: A case-control study.

Authors:  Mohan Kumar H; Prashant Sharma; Shivaprakash M Rudramurthy; Inderpaul Singh Sehgal; Kuruswamy Thurai Prasad; Ashok Kumar Pannu; Reena Das; Naresh K Panda; Navneet Sharma; Arunaloke Chakrabarti; Ritesh Agarwal; Valliappan Muthu
Journal:  Mycoses       Date:  2021-11-16       Impact factor: 4.931

Review 7.  Iron Assimilation during Emerging Infections Caused by Opportunistic Fungi with emphasis on Mucorales and the Development of Antifungal Resistance.

Authors:  Felicia Adelina Stanford; Kerstin Voigt
Journal:  Genes (Basel)       Date:  2020-10-30       Impact factor: 4.096

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.